Is there anything good in uric acid?

QJM: An International Journal of Medicine

Volumn 104, Issue 12, 2011, Pages 1015-1024

  Alvarez Lario B ^a   Macarron vicente J ^a  

^a HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TAMM HORSFALL GLYCOPROTEIN; URIC ACID;

ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; FANCONI RENOTUBULAR SYNDROME; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; IMMUNOREACTIVITY; INFLAMMATION; METABOLIC SYNDROME X; MORTALITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; URIC ACID BLOOD LEVEL; UROLITHIASIS;

EID: 82855181731     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcr159     Document Type: Review

References (86)

1. Richette P, Bardin T. Gout. Lancet 2010; 375:318-28.
2. Alvarez-Lario B, Macarrón-Vicente J. Uric acid and evolution. Rheumatology 2010; 49:2010-5.
3. Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359:1811-21.
4. Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A. Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol 2008; 167:831-8.
5. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, et al. Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2006; 21:344-8.
6. Rentzos M, Nikolaou C, Anagnostouli M, Rombos A, Tsakanikas K, Economou M, et al. Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg 2006; 108:527-31.
7. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risk and consequences in the Normative Aging Study. Am J Med 1987; 82:421-6.
8. Pak CY, Moe OW, Sakhaee K, Peterson RD, Poindexter JR. Physicochemical metabolic characteristics for calcium oxalate stone formation in patients with gouty diathesis. J Urol 2005; 173:1606-9.
9. Kamel KS, Cheema-Dhadli S, Shafiee MA, Davids MR, Halperin ML. Recurrent uric acid stones. QJM 2005; 98:57-68.
10. Yu TF. Urolithiasis in hyperuricemia and gout. J Urol 1981; 126:424-30.
11. Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999; 33:225-34.
12. Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 2009; 18:526-30.
13. Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009; 169:342-50.
14. Chien KL, Lin HJ, Lee BC, Hsu HC, Lee YT, Chen MF. A prediction model for the risk of incident chronic kidney disease. Am J Med 2010; 123:836-846.e2.
15. Iseki K, Ikemiya Y, Kinjo K, Iseki C, Takishita S. Prevalence of high fasting plasma glucose and risk of developing end-stage renal disease in screened subjects in Okinawa, Japan. Clin Exp Nephrol 2004; 8:250-6.
16. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007; 39:1227-33.
17. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47:51-9.
18. Wu CH, Lee CT, Lee CH, Cheng TT, Chang HW, Lin E, et al. Urinary UMOD excretion and chronic kidney disease in gout patients: cross-sectional case-control study. Ren Fail 2011; 33:164-8.
19. Fairbanks LD, Cameron JS, Venkat-Raman G, Rigden SP, Rees L, Van'T Hoff W, et al. Early treatment with allopurinol in familial juvenile hyerpuricaemic nephropathy (FJHN) ameliorates the long-term progression of renal disease. QJM 2002; 95:597-607.
20. Puig JG, Prior C, Martínez-Ara J, Torres RJ. Familial nephropathy associated with hyperuricemia in Spain: our experience with 3 families harbouring a UMOD mutation. Nucleos Nucleot Nucl 2006; 25:1295-300.
21. Mazzali M, Kanbay M, Segal MS, Shafiu M, Jalal D, Feig D, et al. Uric acid and hypertension: cause or effect? Curr Rheumatol Rep 2010; 12:108-17.
22. Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol 2007; 18:287-92.
23. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on the blood pressure of adolescents with newly diagnosed essential hypertension. JAMA 2008; 300:924-32.
24. Johnson RJ, Feig DI, Nakagawa T, Sanchez-Lozada LG, Rodriguez-Iturbe B. Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens 2008; 26:381-91.
25. Zhang W, Sun K, Yang Y, Zhang H, Hu FB, Hui R. Plasma uric acid and hypertension in a Chinese community: prospective study and metaanalysis. Clin Chem 2009; 55:2026-34.
26. Grayson PC, Kim SY, Lavalley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res 2011; 63:102-10.
27. Chien KL, Chen MF, Hsu HC, Chang WT, Su TC, Lee YT, et al. Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin Chem 2008; 54:310-6.
28. Bhole V, Choi JW, Kim SW, de Vera M, Choi H. Serum uric cid levels and the risk of type 2 diabetes: a prospective study. Am J Med 2010; 123:957-61.
29. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120:442-7.
30. Sánchez-Lozada LG, Tapia E, Bautista-García P, Soto V, Avila-Casado C, Vega-Campos IP, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2008; 294:F710-8.
31. Dao HH, Harun-Or-Rashid M, Sakamoto J. Body composition and metabolic syndrome in patients with primary gout in Vietnam. Rheumatology 2010; 49:2400-7.
32. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 2009; 61:225-32.
33. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131:7-13.
34. Waring WS, Webb DJ, Maxwell SRJ. Uric acid as a risk factor for cardiovascular disease. QJM 2000; 93:707-13.
35. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res 2010; 62:170-80.
36. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009; 61:885-92.
37. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008; 168:1104-10.
38. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116:894-900.
39. Niskanen LK, Laaksonen DE, Nyyssönen K, Alfthan G, Lakka HM, Lakka TA, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164:1546-51.
40. Tsai TH, Chen YL, Chen SM, Yang CH, Fang CY, Hsieh YK, et al. Uric Acid is not an independent predictor of cardiovascular death in patients with angiographically proven coronary artery disease. Chang Gung Med J 2009; 32:605-13.
41. Strasak A, Ruttmann E, Brant L, Kelleher C, Klenk J, Concin H, et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem 2008; 54:273-84.
42. Strasak AM, Kelleher CC, Brant LJ, Rapp K, Ruttmann E, Concin H, et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int J Cardiol 2008; 125:232-9.
43. Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology 2010; 49:141-6.
44. Wu X, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992; 34:78-84.
45. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in human against oxidant -and radical- caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981; 78:6858-62.
46. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, et al. Uric acid, hominoid evolution and the pathogenesis of salt-sensitivity. Hypertensión 2002; 40:355-60.
47. Mount DB, Kwon CY, Zandi-Nejad K. Renal urate transport. Rheum Dis Clin North Am 2006; 32:313-31.
48. Cameron JS, Simmonds HA. Uric acid, gout and the kidney. J Clin Pathol 1981; 34:1245-54.
49. Sofaer JA, Emery AEH. Genes for super-intelligence? J Med Genet 1981; 18:410-3.
50. Parmar MS. Uric acid and cardiovascular risk. N Engl J Med 2009; 360:539.
51. Johnson RJ, Rideout BA. Uric acid and diet-insights into epidemic of cardiovascular disease. N Engl J Med 2004; 350:1071-3.
52. Glantzounis G, Tsimoyiannis E, Kappas A, Galaris D. Uric acid and oxidative stress. Curr Pharm Des 2005; 11:4145-51.
53. Jang YC, Pérez VI, Song W, Lustgarten MS, Salmon AB, Mele J, et al. Overexpression of Mn superoxide dismutase does not increase life span in mice. J Gerontol A Biol Sci Med Sci 2009; 64:1114-25.
54. Zhang Y, Ikeno Y, Qi W, Chaudhuri A, Li Y, Bokov A, et al. Mice deficient in both Mn superoxide dismutase and glutathione peroxidase-1 have increased oxidative damage and a greater incidence of pathology but no reduction in longevity. J Gerontol A Biol Sci Med Sci 2009; 64:1212-20.
55. Strasak AM, Rapp K, Hilbe W, Oberaigner W, Ruttmann E, Concin H, et al. Serum uric acid and risk of cancer mortality in a large prospective male cohort. Cancer Causes Control 2007; 18:1021-9.
56. Strasak AM, Rapp K, Hilbe W, Oberaigner W, Ruttmann E, Concin H, et al. The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28 000 older Austrian women. Ann Oncol 2007; 18:1893-7.
57. Boffeta P, Nordenvall C, Nyren O, Ye W. A prospective study of gout and cancer. Eur J Cancer Prev 2009; 18:127-32.
58. Kutzing MK, Firestein BL. Altered uric acid levels and disease states. J Pharmacol Exp Ther 2008; 324:1-7.
59. Scott GS, Hooper DC. The role of uric acid in protection against peroxynitrite-mediated pathology. Med Hypotheses 2001; 56:95-100.
60. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, et al. Urate as predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009; 66:1460-8.
61. Toncev G, Milicic B, Toncev S, Samardzic G. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 2002; 9:221-6.
62. Guerrero AL, Martín-Polo J, Laherrán E, Gutiérrez F, Iglesias F, Tejero MA, et al. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment. Eur J Neurol 2008; 15:394-7.
63. Spitsin S, Markowits CE, Zimmerman V, Koprowski H, Hooper DC. Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect blood pressure. J Hum Hypertens 2010; 24:359-62.
64. Andreadou E, Nikolaou C, Gournaras F, Rentzos M, Boufidou F, Tsoutsou A, et al. Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg 2009; 111:724-8.
65. Chen H, Mosley TH, Alonso A, Huang X. Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2009; 169:1064-9.
66. Winquist A, Steenland K, Shankar A. Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community-based survey. Mov Disord 2010; 25:932-6.
67. O'Reilly EJ, Gao X, Weisskopf MG, Chen H, Schwarzschild MA, Spiegelman D, et al. Plasma urate and Parkinson's disease in women. Am J Epidemiol 2010; 172:666-70.
68. Annanmaki T, Pessala-Driver A, Hokkanen L, Murros K. Uric acid associates with cognition in Parkinson's disease. Parkinsonism Relat Disord 2008; 14:576-8.
69. Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, et al. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 2009; 6:23-8.
70. Waugh WH. Inhibition of iron-catalyzed oxidations by attainable uric acid and ascorbic acid levels: therapeutic implications for Alzheimer's disease and late cognitive impairment. Gerontology 2008; 54:238-43.
71. Ruggiero C, Cherubini A, Lauretani F, Bandinelli S, Maggio M, Di Iorio A, et al. Uric acid and dementia in community-dwelling older persons. Dement Geriatr Cogn Disord 2009; 27:382-9.
72. Vannorsdall TD, Jinnah HA, Gordon B, Kraut M, Schretlen DJ. Cerebral ischemia mediates the effect of serum uric acid on cognitive function. Stroke 2008; 39:3418-20.
73. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34:1951-6.
74. Brouns R, Wauters A, Van de Vijver G, De Surgeloose D, Sheorajpanday R, De Deyn PP. Decrease in uric acid in acute ischemic stroke correlates with stroke severity, evolution and outcome. Clin Chem Lab Med 2010; 48:383-90.
75. Zhang B, Gao C, Yang N, Zhang W, Song X, Yin J, et al. Is elevated SUA associated with a worse outcome in young Chinese patients with acute cerebral ischemic stroke? BMC Neurol 2010; 10:82.
76. Waring WS. Uric acid: an important antioxidant in acute ischaemic stroke. QJM 2002; 95:691-3.
77. Romanos E, Planas AM, Amaro S, Chamorro A. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 2007; 27:14-20.
78. Amaro S, Urra X, Gómez-Choco M, Obach V, Cervera A, Vargas M, et al. Uric acid levels are relevant in patients with stroke treated with thrombolysis. Stroke 2011; 42(1 Suppl):S28-32.
79. Keizman D, Ish-Shalom M, Berliner S, Maimon N, Vered Y, Artamonov I, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci 2009; 285:95-9.
80. Auinger P, Kieburtz K, McDermott MP. The relationship between uric acid levels and Huntington's disease progression. Mov Disord 2010; 25:224-8.
81. Scott GS, Cuzzocrea S, Genovese T, Koprowski H, Hooper DC. Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci USA 2005; 102:3483-8.
82. Busso N, So A. Mechanism of inflammation in gout. Arthritis Research & Therapy 2010; 12:206.
83. Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Clin Rheumatol Rep 2011; 13:160-6.
84. Shi Y, Mucsi AD, Ng G. Monosodium urate crystals in inflammation and immunity. Immunol Rev 2010; 233:203-17.
85. Martinon F. Update on biology: uric acid and the activation of immune and inflammatory cells. Curr Rheumatol Rep 2010; 12:135-41.
86. Johnson RJ, Sautin YY, Oliver WJ, Roncal C, Mu W, Sanchez-Lozada LG, et al. Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society? J Com Physiol B 2009; 179:67-76.